Prolongación del intervalo QT inducido por fármacos: ¿conocemos sus riesgos?

Asmundis, 2013, Epidemiología de la muerte súbita cardiaca, Rev Esp Cardiol, 13, 2 Marrugat, 1999, Muerte súbita (I). Epidemiología de la muerte súbita cardiaca en España, Rev Esp Cardiol, 52, 717, 10.1016/S0300-8932(99)74993-6 Pratt, 1996, Exploration of the precision of classifying sudden cardiac death: Implications for the interpretation of clinical trials, Circulation, 93, 519, 10.1161/01.CIR.93.3.519 Josephson, 2004, Implantable defibrillators and sudden cardiac death, Circulation, 109, 2685, 10.1161/01.CIR.0000129322.97266.F3 Zipes, 1998, Sudden cardiac death, Circulation, 98, 2334, 10.1161/01.CIR.98.21.2334 Van Noord, 2010, Drug- and non-drug-associated QT interval prolongation, Br J Clin Pharmacol, 70, 16, 10.1111/j.1365-2125.2010.03660.x De Ponti, 2002, Safety of non-antiarrythmic drugs that prolong the QT interval or induce tosade de pointes: An overview, Drug Saf, 25, 263, 10.2165/00002018-200225040-00004 Roden, 2004, Drug-induced prolongation of the QT interval, N Engl J Med, 350, 1013, 10.1056/NEJMra032426 Shah, 2013, Drug-induced QT interval prolongation: Does ethnicity of the thorough QT study population matter?, Br J Clin Pharmacol, 75, 347, 10.1111/j.1365-2125.2012.04415.x International Conference on Harmonization. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential of nonantiarrhythmic drugs. EMA/CHMP/ICH/310133/2008. ICH guideline E14, 2012. Food and Drug Administration. International conference harmonization guidance for industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. FDA; 2005 [consultado 21 Ene 2014]. Disponible en: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073 153.pdf. Selzer, 1964, Quinidine syncope, paroxysmal ventricular fibrillations occurring during treatment of chronic atrial arrythmias, Circulation, 30, 17, 10.1161/01.CIR.30.1.17 Dessertenne, 1966, La tachycardie ventricularie à deux froyers opposés variables, Arch Mal Coeur Vaiss, 59, 263 Drew, 2010, Prevention of torsade de pointes in hospitals settings: A scientific statement from the American Heart Association and American College of Cardiology Foundation, Circulation, 121, 1047, 10.1161/CIRCULATIONAHA.109.192704 Hohnloser, 1994, Amiodarone-associated proarrhythmic effects. A review with special reference to torsades de pointes tachycardia, Ann Intern Med, 121, 529, 10.7326/0003-4819-121-7-199410010-00009 Woosley, 1993, Mechanism of the cardiotoxic actions of terfenadine, JAMA, 269, 1532, 10.1001/jama.1993.03500120070028 Yap, 2003, Drug induced QTprolongation and torsades de pointes, Heart, 89, 1363, 10.1136/heart.89.11.1363 Owens, 2006, Antimicrobials-associated QT interval prologation: Points of interest, Clin Infect Dis, 43, 1603, 10.1086/508873 Zambon, 2009, Effect of macrolide and fluoroquinolone antibacterials on the risk of ventricular arrhythmia and cardiac arrest, Drug Saf, 32, 159, 10.2165/00002018-200932020-00008 Vogt, 1997, Long Q-T syndrome associated with oral erythromycin used in preoperative bowel preparation, Anesth Analg, 85, 1011, 10.1213/00000539-199711000-00010 Tschida, 1996, QTc-interval prolongation associated with slow intravenous erythromycin lactobionate infusions in critically ill patients: A prospective evaluation and review of the literature, Pharmacotherapy, 16, 663 Drici, 1998, Cardiac actions of erythromycin: Influence of female sex, JAMA, 280, 1774, 10.1001/jama.280.20.1774 Shaffer, 2002, Concomitant risk factors in reports of torsades de pointes associated with macrolide use: Review of the United States Food and Drug Administration Adverse Event Reporting System, Clin Infect Dis, 35, 197, 10.1086/340861 Ray, 2004, Oral erythromycin use and the risk of sudden cardiac death, N Engl J Med, 351, 1089, 10.1056/NEJMoa040582 Straus, 2005, Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death, Eur Heart J, 26, 2007, 10.1093/eurheartj/ehi312 Poluzzi, 2009, Drug-induced torsades de pointes: Data mining of the public version of the FDA Adverse Event Reporting System (AERS), Pharmacoepidemiol Drug Saf, 18, 512, 10.1002/pds.1746 Ray, 2012, Azithromycin and the risk of cardiovascular death, N Engl J Med, 366, 1881, 10.1056/NEJMoa1003833 Anson, 2005, Blockade of HERG channels by HIV protease inhibitors, Lancet, 365, 682, 10.1016/S0140-6736(05)17950-1 Hunt, 2011, Protease inhibitor-associated QT interval prolongation, Ann Pharmacother, 45, 1544, 10.1345/aph.1Q422 Tarabar, 2008, Citalopram overdose: Late presentation of torsades de pointes (TdP) with cardiac arrest, J Med Toxicol, 4, 101, 10.1007/BF03160963 Chung, 2008, Management of ventricular dysrhythmia secondary to trazadone overdose, J Emerg Med, 35, 171, 10.1016/j.jemermed.2007.02.036 Ray, 2009, Atypical antipsychotic drugs and the risk of sudden cardiac death, N Engl J Med, 360, 225, 10.1056/NEJMoa0806994 CredibleMeds. Composite list of all QTdrugs and the list of drugs to avoid for patients with congenital LQTS [consultado 25 Oct 2013]. Disponible en: http://www.crediblemeds.org/everyone/composite-list-all-qtdrugs/?rf=All Al-Khatib, 2003, What clinicians should know about the QT interval, JAMA, 289, 2120, 10.1001/jama.289.16.2120 Armahizer, 2013, Drug-drug interaccions contributing to QT prolongation in cardiac intensive care units, J Crit Care, 28, 243, 10.1016/j.jcrc.2012.10.014 Zipes, 2006, J Am Coll Cardiol, 48, e247, 10.1016/j.jacc.2006.07.010 Li, 2010, Drug-induced QT-interval prolongation: Considerations for clinicians, Pharmacotherapy, 30, 684, 10.1592/phco.30.7.684 Villamañán, 2011, Prescripción electrónica asistida como nueva tecnología para la seguridad del paciente hospitalizado, Med Clin (Barc), 136, 398, 10.1016/j.medcli.2010.02.012 Mayo Clinic Creates Institution. Wide electronic prolonged QT interval warning system [consultado 25 Oct 2013]. Disponible en: http://newsnetwork.mayoclinic.org/discussion/first-electronic-prolonged-qt-interval-warning-system.